Biogen ALS drug considered not effective by FDA advisory panel
Biogen Inc. (BIIB) received a setback late Wednesday after a Food and Drug Administration advisory committee said the biotech drug maker's proposed amyotrophic lateral sclerosis, or ALS, treatment did not show it was effective. On Wednesday, the FDA's Peripheral and Central Nervous System Drugs Advisory Committee voted 5-3 with one abstention that the study did not "provide convincing evidence of the effectiveness of toferson," the name of the treatment for the proposed indication. While the FDA uses the committee's recommendation to decide whether or not to approve the drug, it is not bound by the decision. Biogen shares were up 0.3% after hours, following a 1.9% decline in the regular session to $261.22.
-Wallace Witkowski
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
03-22-23 1828ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
Going Into Earnings, Is Microsoft a Buy, a Sell, or Fairly Valued?
-
Big Banks: High Interest Rates and Sticky Inflation Haven’t Dented Consumer Spending
-
Is the World Deglobalizing?
-
How to Position Your Investment Portfolio Before the 2024 Election
-
Q2 Update: 2024 Outlook for the Stock Market and Economy
-
6 Stocks to Sell and 6 Stocks to Buy Instead
-
Markets Brief: Will the New Inflation Story Hurt Stocks?
-
Magnificent No More? Apple and Tesla Stocks Are Weighing on the Market
-
Lithium Americas: Shares Plunge on Equity Issuance
-
4 Undervalued Semiconductor Stocks
-
Comerica Earnings: Net Interest Income and Expense Outlook Steady
-
Kinder Morgan Earnings: AI Growth Likely to Add Second Leg to Gas Demand on Top of US LNG Exports
-
Going Into Earnings, Is Meta Stock a Buy, a Sell, or Fairly Valued?
-
United Airlines Earnings: Strong Revenue Offset by Ongoing Investments
-
19 Best Healthcare Companies to Invest In
-
US Bancorp Earnings: Company Lowers 2024 Guidance for Both Net Interest Income and Expense